HEAL 1UG3DA050942-01A1: Effect of intranasal pGDNF nanoparticles on oxycodone reinstatement using IVSA

Published: 14 January 2026| Version 1 | DOI: 10.17632/38hmy7ssgm.1
Contributor:
Elizabeth Byrnes

Description

This dataset contains behavioral data from male and female rats examining the effects of intranasal pGDNF (plasmid glial cell line-derived neurotrophic factor) DNA nanoparticles on oxycodone seeking behavior. Following jugular catheterization surgery, rats underwent oxycodone self-administration training using a fixed-ratio schedule (FR1 and FR5) over 12 days, followed by a progressive ratio test on Day 13. On Day 14, rats received intranasal infusions of either saline (VEH) or pGDNF nanoparticles under anesthesia. Following 27 days of forced abstinence, oxycodone seeking was assessed via a 90-minute reinstatement test on Day 42. Data include: active and inactive lever presses, oxycodone infusions earned, breakpoint values, body weights, and withdrawal monitoring scores across all experimental phases. Group sizes: Male VEH (n=17), Female VEH (n=15), Male GDNF (n=16), Female GDNF (n=17). This dataset also includes all intravenous self-administration (IVSA) data through Day 14 for subjects used in central dopamine exocytosis studies conducted by collaborator Dr. Emmanuel Pothos. The corresponding electrophysiology dataset is available at doi: 10.17632/mz25fgvtv2.1 Supported by NIH HEAL Initiative grant 1UG3DA050942-01A1.

Files

Steps to reproduce

See "Experimental Design" tab in the uploaded dataset for full methods, timelines, drug doses, and group assignments.

Categories

Behavioral Neuroscience, Animal Model, Behavioral Pharmacology, Opioid Abuse, Substance Abuse

Funders

  • NIH HEAL Initiative
    Grant ID: 1UG3DA050942-01A1

Licence